EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework

Aliasgar F Shahiwala

Pharmaceutical Science Advances · 2026-12 · 4 · 100122

DOI: 10.1016/j.pscia.2026.100122 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Aliasgar F Shahiwala. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Dubai Medical University, Dubai, United Arab Emirates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Microsoft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceuticals have long demonstrated precise, organ- and receptor-specific targeting in humans, supported by well-characterized pharmacokinetics, standardized formulation, and regulatory validation; however, the carrier systems underlying these agents remain largely underexplored as platforms for therapeutic delivery. This review introduces a translational framework that repositions clinically validated radiopharmaceutical carriers, including peptides, nanocolloids, lipophilic complexes, and antibody fragments, as ready-to-deploy scaffolds for targeted drug delivery and theranostic applications. Integrating classical radiopharmaceutical principles with advances from 2018 to 2025, this work examines how established systems based on technetium-99m (99ᵐTc), gallium, lutetium, rhenium, copper, iodine, and actinium can be systematically re-engineered through linker design, bifunctional chelation, and payload integration. Unlike conventional nanocarriers that rely heavily on preclinical optimization and passive targeting mechanisms, these platforms offer pre-validated human biodistribution, reproducible pharmacokinetics, and compatibility with good manufacturing practice (GMP), providing a distinct advantage for clinical translation. Emerging clinical evidence, including peptide-drug conjugates and antibody-based systems, highlights both the feasibility and current limitations of this approach, particularly the gap between diagnostic success and therapeutic adaptation. By integrating mechanistic insights, design strategies, and translational considerations, this review proposes a shift from de novo carrier design toward the strategic repurposing of clinically proven systems, with the potential to reduce translational attrition and accelerate the development of precision therapeutics and next-generation theranostic platforms.

Schlagwörter

Stichwörter der Autor:innen

Linker engineeringRadiopharmaceutical repurposingTargeted drug deliveryTechnetium-99mTheranostics

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Dubai Medical University, Dubai, United Arab Emirates.

Förderung

  • Microsoft

Zitieren

APA

Shahiwala, A. F. (2026). Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework. Pharmaceutical Science Advances, 4, 100122. https://doi.org/10.1016/j.pscia.2026.100122

Vancouver

Shahiwala AF. Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework. Pharmaceutical Science Advances. 2026;4:100122. doi:10.1016/j.pscia.2026.100122

BibTeX
@article{Shahiwala2026,
  author = {Shahiwala, Aliasgar F},
  title = {Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework},
  journal = {Pharmaceutical Science Advances},
  year = {2026},
  volume = {4},
  pages = {100122},
  doi = {10.1016/j.pscia.2026.100122}
}
Kostenlos starten →